vonoprazan + amoxicillin + metronidazole

This drug is a **combination regimen** consisting of vonoprazan, amoxicillin, and metronidazole, used primarily for the first-line eradication of *Helicobacter pylori* infection, especially in patients with clarithromycin-resistant strains or in cases where clarithromycin or penicillin cannot be used. - **Vonoprazan** is a potassium-competitive acid blocker (PCAB) that strongly inhibits gastric acid secretion, providing an optimal environment for the antibiotics to work effectively. - **Amoxicillin** is a beta-lactam antibiotic active against *H. pylori* by inhibiting cell wall synthesis. - **Metronidazole** is a nitroimidazole antibiotic and antiprotozoal, active against anaerobic bacteria such as *H. pylori*, particularly effective in clarithromycin- or penicillin-resistant cases. The combination has been shown to achieve high eradication rates in various clinical studies, and regimens of vonoprazan + amoxicillin + metronidazole are recommended or studied especially in populations with specific antibiotic resistance or allergies[1][6]. This specific triple therapy regimen is often referred to as VPZ-AMPC-MNZ in the literature[1].

Other names

VPZ-AMPC-MNZ